Cannabigerol May Help in Treating Nonalcoholic Fatty Liver Disease, New Study Suggests
A study published in January 2023 examined the effects of high and low doses of cannabigerol (CBG) on mice liver.
Cannabigerol (CBG) may have therapeutic potential when treating nonalcoholic fatty liver disease (NAFLD), concluded a study published by researchers at the Universities of Utah and Northern Colorado (1). The study, published in MDPI in the Special Issue "Liver Disease, Lifestyle and Cardiovascular Risk,” analyzed the effects of CBG on hepatic steatosis, fibrosis, and inflammation connected to NAFLD (1). Scientists analyzed the livers of mice after being separated into groups, fed specific diets, then given either low or high doses of CBG.
“Overall, our results suggest that the low dose of CBG treatment has a higher potential for alleviating liver damage due to methionine/choline-deficient (MCD)-induced non-alcoholic steatohepatitis (NASH) symptoms, compared to high dose of CBG, which caused elevated liver damage,” read part of the study’s results section (2). “In conclusion, this study provides initial findings and a foundation for future studies on the efficacy of CBG on NASH.”
CBG is called “The Mother Cannabinoid” because all other cannabinoids derive from it. CBG also has potential anti-inflammatory effects similar to other cannabinoids and is non-psychotropic (1,2).
References
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Kahn
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
